Organization And Business Activities (Details) (USD $)	0 Months Ended	3 Months Ended	0 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended		3 Months Ended
	Apr. 10, 2012	Mar. 31, 2012	Nov. 03, 2011 DuoCort Pharma AB [Member] Y	Nov. 15, 2011 DuoCort Pharma AB [Member]	Sep. 30, 2011 Maximum [Member] Y	Mar. 31, 2012 Maximum [Member] M Y	Sep. 30, 2011 Minimum [Member] M	Mar. 31, 2012 Minimum [Member] M	May 31, 2010 Auralis Limited [Member]	Mar. 31, 2012 Year One [Member]	Mar. 31, 2012 Year Two [Member]	Mar. 31, 2012 Year Three [Member]
Organization And Business Activities [Line Items]
Number of years of exclusivity	3
Royalties payment										10.00%	10.00%	16.00%
Number of ANDAs	$ 3
Percentage of qualitative assessment for testing goodwill for impairment		50.00%
Ownership interest				100.00%					100.00%
Age of children and adolescents for the purpose of being eligible for treatment					18	18	3	3
Time taken to initiate phase 2 study from the date of agreement, in months						18		12
Years for pharmaceutical innovation of orphan drug			50
Inventory Adjustments		$ 400,000